Microbiology and Immunology

You are here

Publications

Found 357 results

Author Title Type [ Year

]

Filters: First Letter Of Last Name is W [Clear All Filters]

2025

Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al.. 2025. Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.

Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al.. 2025. Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.

Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al.. 2025. Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.

Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al.. 2025. Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.

Dupnik KM, Dorvil N, Ward M, Rivera V, Apollon A, Dumont E, Sued O, Pape JW, Koenig SP. 2025. Histoplasma capsulatum Not Detected in People with HIV and Systemic Symptoms in Port-au-Prince, Haiti.. AIDS Res Hum Retroviruses.

Klasse PJ, Sanders RW, Ward AB, Wilson IA, Moore JP. 2025. The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.. Nat Rev Microbiol.

Klasse PJ, Sanders RW, Ward AB, Wilson IA, Moore JP. 2025. The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.. Nat Rev Microbiol.

Green SR, Harrison JR, Thompson S, Murugesan D, M Libardo DJ, Engelhart CA, Meshanni J, Fletcher D, Scullion P, Edwards D et al.. 2025. Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of Mycobacterium tuberculosis.. ACS Infect Dis. 11(3):715-726.

Johnson WC, Alivisatos A, Smith TC, Van N, Soni V, Wallach JB, Clark NA, Fitzgerald TA, Whiteley JJ, Tan S et al.. 2025. Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action.. Cell Syst. :101348.

Johnson WC, Alivisatos A, Smith TC, Van N, Soni V, Wallach JB, Clark NA, Fitzgerald TA, Whiteley JJ, Tan S et al.. 2025. Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action.. Cell Syst. :101348.

Liu Q, Engelhart CA, Wallach JB, Tiwari D, Ge P, Manna A, Panda S, McCue WM, Wong T-Y, Sharma S et al.. 2025. Metabolically Stable Adenylation Inhibitors of Biotin Protein Ligase as Antibacterial Agents.. J Med Chem. 68(3):3065-3087.

Liu Q, Engelhart CA, Wallach JB, Tiwari D, Ge P, Manna A, Panda S, McCue WM, Wong T-Y, Sharma S et al.. 2025. Metabolically Stable Adenylation Inhibitors of Biotin Protein Ligase as Antibacterial Agents.. J Med Chem. 68(3):3065-3087.

Zhang M, Allen R, Ames L, Engelhart CA, Quach D, Lv X, Xiao G, Wang H, Wang J, Zhou L et al.. 2025. Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.. Antimicrob Agents Chemother. :e0036825.

Zhang M, Allen R, Ames L, Engelhart CA, Quach D, Lv X, Xiao G, Wang H, Wang J, Zhou L et al.. 2025. Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.. Antimicrob Agents Chemother. :e0036825.

Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K et al.. 2025. Precise targeting of HIV broadly neutralizing antibody precursors in humans.. Science. 389(6759):eadv5572.

Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K et al.. 2025. Precise targeting of HIV broadly neutralizing antibody precursors in humans.. Science. 389(6759):eadv5572.

Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K et al.. 2025. Precise targeting of HIV broadly neutralizing antibody precursors in humans.. Science. 389(6759):eadv5572.

Xu A, Ayoub S, Zhang H, Wu Y, Rau M, Ma X. 2025. Regulatory T Cells in Invasive Breast Cancer: Prognosis, Mechanisms and Therapy.. Cancers (Basel). 17(19)

Kassegne K, Shen H-M, Chen S-B, Xu S-J, Li J, Xu B, Deitsch KW, Wang Y, Zhou X-N, Chen J-H. 2025. A subset of Plasmodium falciparum RIFINs is linked to severe malaria risk reduction and engages LILRB1 through a conserved structural motif.. EBioMedicine. 122:106041.

Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D et al.. 2025. SuFEx-based antitubercular compound irreversibly inhibits Pks13.. Nature.

Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D et al.. 2025. SuFEx-based antitubercular compound irreversibly inhibits Pks13.. Nature.

Mostert D, Braun J, Zimmerman MD, Engelhart CA, Berndl S, Quoika PK, Kany AM, Proietto J, Penalva-Lopez S, Wallach JB et al.. 2025. Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly.. Chem Sci. 16(21):9472-9483.

2026

Seshadri C, Flynn JAL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ et al.. 2026. Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.. Lancet Microbe. :101278.

Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al.. 2026. Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.

Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al.. 2026. Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.